Original articles
Pingping Luo, Ming Zheng, Rui Zhang, Hong Zhang, Yingxia Liu, Wei Li, Xiaoming Sun, Qian Yu, George L. Tipoe, Jia Xiao. S-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling[J]. Acta Pharmaceutica Sinica B, 2021, 11(3): 668-679

S-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling
Pingping Luoa, Ming Zhengb, Rui Zhanga, Hong Zhangb, Yingxia Liuc, Wei Lid, Xiaoming Sune, Qian Yuf, George L. Tipoef, Jia Xiaoa,f
a Clinical Medicine Research Institute, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China;
b Department of Interventional Surgery, the First Affiliated Hospital of Jinan University, Guangzhou 510632, China;
c State Key Discipline of Infectious Diseases, Department of Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen 518000, China;
d Faculty of Pharmaceutical Sciences, Toho University, Chiba 2748510, Japan;
e School of Integrative Pharmacy, Institute of Integrative Pharmaceutical Research, Guangdong Pharmaceutical University, Guangzhou 510000, China;
f School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong 999077, China
Abstract:
Alcoholic liver disease (ALD) causes insulin resistance, lipid metabolism dysfunction, and inflammation. We investigated the protective effects and direct regulating target of S-allylmercaptocysteine (SAMC) from aged garlic on liver cell injury. A chronic ethanol-fed ALD in vivo model (the NIAAA model) was used to test the protective functions of SAMC. It was observed that SAMC (300 mg/kg, by gavage method) effectively ameliorated ALD-induced body weight reduction, steatosis, insulin resistance, and inflammation without affecting the health status of the control mice, as demonstrated by histological, biochemical, and molecular biology assays. By using biophysical assays and molecular docking, we demonstrated that SAMC directly targeted insulin receptor (INSR) protein on the cell membrane and then restored downstream IRS-1/AKT/GSK3β signaling. Liver-specific knock-down in mice and siRNA-mediated knock-down in AML-12 cells of Insr significantly impaired SAMC (250 μmol/L in cells)-mediated protection. Restoration of the IRS-1/AKT signaling partly recovered hepatic injury and further contributed to SAMC’s beneficial effects. Continuous administration of AKT agonist and recombinant IGF-1 in combination with SAMC showed hepato-protection in the mice model. Long-term (90-day) administration of SAMC had no obvious adverse effect on healthy mice. We conclude that SAMC is an effective and safe hepato-protective complimentary agent against ALD partly through the direct binding of INSR and partial regulation of the IRS-1/AKT/GSK3β pathway.
Key words:    Alcoholic liver disease    S-Allylmercaptocysteine    Insulin receptor    Insulin resistance    IRS-1    AKT    GSK3β    Safety   
Received: 2020-06-29     Revised: 2020-08-31
DOI: 10.1016/j.apsb.2020.11.006
Funds: This work was supported by National Natural Science Foundation of China (81970515) and Guangdong Natural Science Funds for Distinguished Young Scholar (2019B151502013, China).
Corresponding author: George L. Tipoe, Jia Xiao     Email:edwinsiu@connect.hku.hk;tgeorge@hku.hk
Author description:
Service
PDF(KB) Free
Print
0
Authors
Pingping Luo
Ming Zheng
Rui Zhang
Hong Zhang
Yingxia Liu
Wei Li
Xiaoming Sun
Qian Yu
George L. Tipoe
Jia Xiao

References:
1. Louvet A, Mathurin P. Alcoholic liver disease: Mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol 2015;12: 231-42.
2. Xiao J, Wang F, Wong NK, He J, Zhang R, Sun R, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective. J Hepatol 2019;71:212-21.
3. Liangpunsakul S, Haber P, McCaughan GW. Alcoholic liver disease in Asia, Europe, and North America. Gastroenterology 2016;150: 1786-97.
4. Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, et al. Alcoholic liver disease. Nat Rev Dis Primers 2018;4:16.
5. Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, Terrault NA, et al. The epidemiology and clinical characteristics of patients with newly diagnosed alcohol-related liver disease: Results from population-based surveillance. J Clin Gastroenterol 2010;44:301-7.
6. He J, de la Monte S, Wands JR Wands. Acute ethanol exposure inhibits insulin signaling in the liver. Hepatology 2007;46:1791-800.
7. de la Monte S, Derdak Z, Wands JR. Alcohol, insulin resistance and the liverebrain axis. J Gastroenterol Hepatol 2012;27 Suppl 2: 33-41.
8. Inoue H. Central insulin-mediated regulation of hepatic glucose production. Endocr J 2016;63:1-7.
9. Leavens KF, Birnbaum MJ. Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol 2011;46: 200-15.
10. He L, Simmen FA, Mehendale HM, Ronis MJ, Badger TM. Chronic ethanol intake impairs insulin signaling in rats by disrupting Akt association with the cell membrane. Role of TRB3 in inhibition of Akt/protein kinase B activation. J Biol Chem 2006;281:11126-34.
11. Pang M, de la Monte SM, Longato L, Tong M, He J, Chaudhry R, et al. PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol 2009;50: 1192-201.
12. Zhu X, Jiang X, Li A, Sun Y, Liu Y, Sun X, et al. S-Allylmercaptocysteine suppresses the growth of human gastric cancer xenografts through induction of apoptosis and regulation of MAPK and PI3K/Akt signaling pathways. Biochem Biophys Res Commun 2017; 491:821-6.
13. Li S, Yang G, Zhu X, Cheng L, Sun Y, Zhao Z. Combination of rapamycin and garlic-derived S-allylmercaptocysteine induces colon cancer cell apoptosis and suppresses tumor growth in xenograft nude mice through autophagy/p62/Nrf 2 pathway. Oncol Rep 2017;38: 1637-44.
14. Howard EW, Ling MT, Chua CW, Cheung HW, Wang X, Wong YC. Garlic-derived S-allylmercaptocysteine is a novel in vivo antimetastatic agent for androgen-independent prostate cancer. Clin Canc Res 2007;13:1847-56.
15. Wu J, Zhao S, Zhang J, Qu X, Jiang S, Zhong Z, et al. Over-expression of survivin is a factor responsible for differential responses of ovarian cancer cells to S-allylmercaptocysteine (SAMC). Exp Mol Pathol 2016;100:294-302.
16. Liu Y, Yan J, Han X, Hu W. Garlic-derived compound S-allylmercaptocysteine (SAMC) is active against anaplastic thyroid cancer cell line 8305C (HPACC). Technol Health Care 2015;23 Suppl 1:S89-93.
17. Xiao J, Liong EC, Ling MT, Ching YP, Fung ML, Tipoe GL. SAllylmercaptocysteine reduces carbon tetrachloride-induced hepatic oxidative stress and necroinflammation via nuclear factor kappa Bdependent pathways in mice. Eur J Nutr 2012;51:323-33.
18. Xiao J, Ching YP, Liong EC, Nanji AA, Fung ML, Tipoe GL. Garlicderived S-allylmercaptocysteine is a hepato-protective agent in nonalcoholic fatty liver disease in vivo animal model. Eur J Nutr 2013; 52:179-91.
19. Xiao J, Guo R, Fung ML, Liong EC, Chang RC, Ching YP, et al. Garlic-derived S-allylmercaptocysteine ameliorates nonalcoholic fatty liver disease in a rat model through inhibition of apoptosis and enhancing autophagy. Evid Based Complement Alternat Med 2013; 2013:642920.
20. Xiao J, Xing F, Liu Y, Lv Y, Wang X, Ling MT, et al. Garlic-derived compound S-allylmercaptocysteine inhibits hepatocarcinogenesis through targeting LRP6/Wnt pathway. Acta Pharm Sin B 2018;8: 575-86.
21. Bertola A, Mathews S, Ki SH, Wang H, Gao B. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc 2013;8:627-37.
22. Zeng T, Zhang CL, Zhao N, Guan MJ, Xiao M, Yang R, et al. Impairment of Akt activity by CYP2-1 mediated oxidative stress is involved in chronic ethanol-induced fatty liver. Redox Biol 2018;14: 295-304.
23. Ahn J, Cho I, Kim S, Kwon D, Ha T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J Hepatol 2008;49:1019-28.
24. Schümann J, Prockl J, Kiemer AK, Vollmar AM, Bang R, Tiegs G. Silibinin protects mice from T cell-dependent liver injury. J Hepatol 2003;39:333-40.
25. Brunt EM, Kleiner DE, Wilson LA. Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: Distinct clinicopathologic meanings. Hepatology 2011;53: 810-20.
26. Solon-Biet SM, Mitchell SJ, Coogan SC, Cogger VC, Gokarn R, McMahon AC, et al. Dietary protein to carbohydrate ratio and caloric restriction: Comparing metabolic outcomes in mice. Cell Rep 2015; 11:1529-34.
27. Depetris RS, Hu J, Gimpelevich I, Holt LJ, Daly RJ, Hubbard SR. Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14. Mol Cell 2005;20:325-33.
28. Gondoin A, Hampe C, Eudes R, Fayolle C, Pierre-Eugène C, Miteva M, et al. Identification of insulin-sensitizing molecules acting by disrupting the interaction between the insulin receptor and Grb14. Sci Rep 2017;7:16901.
29. Wang F, Tipoe GL, Yang C, Nanji AA, Hao X, So KF, et al. Lycium barbarum polysaccharide supplementation improves alcoholic liver injury in female mice by inhibiting stearoyl-CoA desaturase 1. Mol Nutr Food Res 2018;62:e1800144.
30. Singal AK, Kodali S, Vucovich LA, Darley-Usmar V, Schiano TD. Diagnosis and treatment of alcoholic hepatitis: A systematic review. Alcohol Clin Exp Res 2016;40:1390-402.
31. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-22.
32. Zhong W, Zhao Y, Tang Y, Wei X, Shi X, Sun W, et al. Chronic alcohol exposure stimulates adipose tissue lipolysis in mice: Role of reverse triglyceride transport in the pathogenesis of alcoholic steatosis. Am J Pathol 2012;180:998-1007.
33. Katayama N, Orita M, Yamaguchi T, Hisamichi H, Kuromitsu S, Kurihara H, et al. Identification of a key element for hydrogenbonding patterns between protein kinases and their inhibitors. Proteins 2008;73:795-801.
34. Huang CK, Yu T, de la Monte SM, Wands JR, Derdak Z, Kim M. Restoration of Wnt/b-catenin signaling attenuates alcoholic liver disease progression in a rat model. J Hepatol 2015;63:191-8.
35. Geng Y, Ju Y, Ren F, Qiu Y, Tomita Y, Tomoeda M, et al. Insulin receptor substrate 1/2 (IRS1/2) regulates Wnt/β-catenin signaling through blocking autophagic degradation of dishevelled 2. J Biol Chem 2014;289:11230-41.
36. Samuel VT, Shulman GI. Mechanisms for insulin resistance: Common threads and missing links. Cell 2012;148:852-71.
37. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000;6:77-86.
38. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metabol 2011;13:376-88.
39. Samuel VT, Shulman GI. The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux. J Clin Invest 2016; 126:12-22.
40. Schrieks IC, Heil AL, Hendriks HF, Mukamal KJ, Beulens JW. The effect of alcohol consumption on insulin sensitivity and glycemic status: A systematic review and meta-analysis of intervention studies. Diabetes Care 2015;38:723-32.
41. Engstler AJ, Aumiller T, Degen C, Dürr M, Weiss E, Maier IB, et al. Insulin resistance alters hepatic ethanol metabolism: Studies in mice and children with non-alcoholic fatty liver disease. Gut 2016;65: 1564-71.
42. de la Monte SM, Pang M, Chaudhry R, Duan K, Longato L, Carter J, et al. Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance. Hepatol Res 2011;41: 386-98.
43. Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of nonalcoholic fatty liver disease. World J Hepatol 2014;6:199-206.
44. Sanyal AJ, Miller V. Regulatory science and drug approval for alcoholic and nonalcoholic steatohepatitis. Gastroenterology 2016;150: 1723-7.
45. Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, O’Grady J. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitisda randomised clinical trial. J Hepatol 2006;44:784-90.
46. Moreno C, Langlet P, Hittelet A, Lasser L, Degré D, Evrard S, et al. Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: A randomized multicenter controlled trial. J Hepatol 2010;53:1117-22.
47. Luo G, Huang B, Qiu X, Xiao L, Wang N, Gao Q, et al. Resveratrol attenuates excessive ethanol exposure induced insulin resistance in rats via improving NAD+/NADH ratio. Mol Nutr Food Res 2017;61: 1700087.
48. Testino G, Leone S, Ansaldi F, Borro P. Silymarin and S-adenosyl-Lmethionine (SAMe): Two promising pharmacological agents in case of chronic alcoholic hepathopathy. A review and a point of view. Minerva Gastroenterol Dietol 2013;59:341-56.
49. Luo P, Wang F, Wong NK, Lv Y, Li X, Li M, et al. Divergent roles of kupffer cell TLR2/3 signaling in alcoholic liver disease and the protective role of EGCG. Cell Mol Gastroenterol Hepatol 2020;9: 145-60.
50. Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol. Free Radic Biol Med 2008;44:723-38.
51. Yang M, Dong Z, Jiang X, Zhao Z, Zhang J, Cao X, et al. Determination of S-allylmercaptocysteine in rat plasma by LCeMS/MS and its application to a pharmacokinetics study. J Chromatogr Sci 2018;56: 396-402.
Similar articles: